Tumor biopsy analysis
tumor
SECONDARY, TUMOR
Planned secondary analyses of baseline tumor biopsies were compared to on-treatment biopsies collected after IFN-γ induction but prior to the administration of nivolumab. Of 21 patients with biopsy specimens evaluable for comparison of PD-L1 expression, TPS was >1% at baseline in 52% of patients (Supplementary Table 